- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT02568540
C Tracker, Hepatitis C, Care & Collaboration - Patient Reported Outcomes Survey Study (CTracker)
preSmartphone App for Monitoring and Reporting of Hepatitis C Related Health Information: C Tracker Hepatitis C, Care & Collaboration - Patient Reported Outcomes Survey Study
Studieöversikt
Status
Betingelser
Detaljerad beskrivning
Specific Aims/Objectives
Aim 1. Develop a free iPhone app ("C TRACKER") designed to anonymously record and report Hepatitis C related health data to study investigators via periodic patient-reported surveys.
Aim 2. Examine the feasibility of enrolling a large cohort of geographically dispersed cohort of subjects with hepatitis C who download and install the C TRACKER app, provide informed consent using the app, and complete study surveys using the app. The app will be made available to the public via the Apple App Store at no cost.
Aim 3. Pilot usage of the app to track and analyze longitudinal measures of hepatitis C related health concerns, physical function, and physical activity via selected disease-specific as well as more broadly applicable patient-reported instruments, including regarding work productivity (WPAI-Hepatitis C), physical functioning (subsets/subscales of the MOS SF-36), physical activity (collected through Apple HealthKit), and prescribed medications.
Studietyp
Inskrivning (Faktisk)
Kontakter och platser
Studieorter
-
-
Massachusetts
-
Boston, Massachusetts, Förenta staterna, 02116
- Children's Hospital Boston
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
Beskrivning
Inclusion Criteria:
- Self-report a diagnosis of Hepatitis C
- English speaking individuals
- 18 years or older
- Must have access to an iPhone that operates on iOS version 8 or higher
- Be able to download apps from the U.S. Apple iPhone Store, and enter data themselves or via a proxy on their behalf
Exclusion Criteria:
• Individuals not meeting inclusion criteria will be excluded.
Studieplan
Hur är studien utformad?
Designdetaljer
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Changes in hepatitis C medication therapy
Tidsram: every 4 months for 2 years
|
Patient reported hepatitis C medication therapy.
Medication type and timing will be compared against other patient-reported outcome measures looking at workforce productivity and physical health and function.
Medication changes will be collected every 4 months (3 times a year).
|
every 4 months for 2 years
|
Changes in Workforce Productivity and Activity Impairment Compared to changes in hepatitis C medication therapy.
Tidsram: every 2 weeks and data will be analyzed every 6 months, for a total of 2 years
|
The Work Productivity and Activity Impairment Questionnaire: Hepatitis C V2.0 (WPAI:Hepatitis C, 6 questions in total) will be administered and compared to changes in Hepatitis C medication therapy.
Measures will be collected every 2 weeks and data will be analyzed every 6 months.
|
every 2 weeks and data will be analyzed every 6 months, for a total of 2 years
|
Changes in Physical Function and Limitations Due to Physical Health Compared to changes in hepatitis C medication therapy.
Tidsram: every 4 months for 2 years; a subset will be analyzed every 2 weeks and data will be analyzed every 6 months, for a total of 2 years
|
3. The Physical Function domain and Role Limitations Due to Physical Health domain of the Medical Outcomes Study (MOS) 36-Item Short Form Survey (14 questions in total) will be administered and compared to changes in Hepatitis C medication therapy.
All questions will be collected every 4 months.
A subset of The Physical Function domain and Role Limitations Due to Physical Health domain of the Medical Outcomes Study (MOS) 36-Item Short Form Survey (5 questions in total) will be administered every 2 weeks.
Data will be analyzed every 6 months.
|
every 4 months for 2 years; a subset will be analyzed every 2 weeks and data will be analyzed every 6 months, for a total of 2 years
|
Samarbetspartners och utredare
Sponsor
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- P00018023
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Hepatit C
-
Dokuz Eylul UniversityEge UniversityAvslutadMMP9 | TIMP1 | MMP9 -1562 C/T | TIMP1 372 T/CKalkon
-
Hadassah Medical OrganizationXTL BiopharmaceuticalsIndragenKronisk hepatit C-virusinfektionIsrael
-
Hadassah Medical OrganizationOkändKronisk hepatit C-virusinfektionIsrael
-
Trek Therapeutics, PBCAvslutadKronisk hepatit C | Hepatit C genotyp 1 | Hepatit C (HCV) | Hepatit C virusinfektionFörenta staterna, Nya Zeeland
-
Trek Therapeutics, PBCAvslutadKronisk hepatit C | Hepatit C (HCV) | Hepatit C genotyp 4 | Hepatit C virusinfektionFörenta staterna
-
Beni-Suef UniversityAvslutadKronisk hepatit C-virusinfektionEgypten
-
Humanity and Health Research CentreBeijing 302 HospitalAvslutadKronisk hepatit C-infektionKina
-
University College CorkDupont Applied BiosciencesRekrytering
-
Tripep ABInovio PharmaceuticalsOkändKronisk hepatit C-virusinfektionSverige
-
Johann Wolfgang Goethe University HospitalAvslutad